Supplement Library
SUPPLEMENT ARTICLE: A Novel Drug Delivery Method: Retrometabolic Drug Design
April 2022 | Volume 21 | Issue 4 | Supplement Individual Articles | s5 | Copyright © April 2022
Soft drugs, a class of retrometabolic drug design, contain a metabolically sensitive moiety that promotes rapid metabolism to inactive metabolites after exerting activity at its target site. The goal ...
Read MoreINTRODUCTION: Retrometabolic Drug Delivery in Dermatology
April 2022 | Volume 21 | Issue 4 | Supplement Individual Articles | Is3 | Copyright © April 2022
A fundamental aspect of dermatologic diagnosis and treatment is our visibly ready access to the site of skin disease. Just as we can often render a diagnosis based on visual assessment of a lesion or ...
Read MoreFULL SUPPLEMENT: DERMATOLOGIC DRUG DESIGN GOES RETRO
April 2022 | Volume 21 | Issue 4 | Department | S1188 | Copyright © April 2022
This supplement aims to provide a brief overview of retrometabolic drug design and a summary of the impact of the retrometabolic approach in other specialties. It highlights the use of retrometabolica...
Read MoreSUPPLEMENT ARTICLE: Scientific and Clinical Insights into the Facial Application of Mineralizing Volcanic Water
April 2022 | Volume 21 | Issue 4 | Supplement Individual Articles | s3 | Copyright © April 2022
Background: The term "exposome" describes the totality of exposures an individual is subjected to from conception to death. Both internal and external exposome factors affect skin hea...
Read MoreFULL SUPPLEMENT: SCIENTIFIC AND CLINICAL INSIGHTS INTO THE USE OF MINERALIZING THERMAL WATER-CONTAINING SERUM FOR REDUCING FACIAL EXPOSOME IMPACT
April 2022 | Volume 21 | Issue 4 | Department | s1 | Copyright © April 2022
This review explores scientific and clinical insights into the exposome impact on facial skin aging and the potential benefits of topical mineralizing volcanic water use....
Read MoreFULL SUPPLEMENT: SKINCARE FOR CANCER PATIENTS AND SURVIVORS IN THE EUROPEAN NORDIC REGION: A REVIEW BY THE NORDIC EUROPEAN CUTANEOUS ONCODERMATOLOGY MANAGEMENT (NECOM) GROUP
December 2021 | Volume 20 | Issue 12 | Department | swp1 | Copyright © December 2021
This supplement covers the Nordic European Cutaneous Oncodermatology Management (NECOM) project, which explored clinical insights and reached a consensus on evidence and opinion-based best practice re...
Read MoreSUPPLEMENT INDIVIDUAL ARTICLE: Skincare for Cancer Patients in Scandinavia
December 2021 | Volume 20 | Issue 12 | Supplement Individual Articles | ss4 | Copyright © December 2021
Preventive measures, earlier diagnosis, and markedly improved anticancer treatments have resulted in increasingly more patients living with or surviving cancer. Frequently cancer treatment-related cut...
Read MoreFULL SUPPLEMENT: ALGORITHM FOR PRE-/POST-PROCEDURE MEASURES FOR FACIAL NONENERGY-BASED AND INJECTABLE SKIN TREATMENTS
November 2021 | Volume 20 | Issue 11 | Department | ss1121 | Copyright © November 2021
A panel of dermatologists and plastic surgeons convened a virtual meeting to develop an algorithm for measures before, during, and after nonenergy and injectable treatments based on the best available...
Read MoreINDIVIDUAL ARTICLE: Algorithm for Nonenergy and Injectable Treatment Pre-/Post-Procedure Measures
November 2021 | Volume 20 | Issue 11 | Supplement Individual Articles | ss3s | Copyright © November 2021
Background: Nonenergy and injectable treatments are frequently used for facial rejuvenation. Many publications have addressed methods to reduce adverse events related to the procedure...
Read MoreINDIVIDUAL ARTICLE: Safety and Tolerability of Topical Agents for Actinic Keratosis: A Systematic Review of Phase 3 Clinical Trials
October 2021 | Volume 20 | Issue 10 | Supplement Individual Articles | s4s4 | Copyright © October 2021
Background: Topical agents for actinic keratosis (AK), along with cryotherapy and phototherapy, are the most commonly used therapies for areas of skin with multiple AKs. Multiple opti...
Read MoreINDIVIDUAL ARTICLE: The Importance of Local Tolerability and Duration of Therapy in Topical Actinic Keratosis Treatment
October 2021 | Volume 20 | Issue 10 | Supplement Individual Articles | s3s3 | Copyright © October 2021
Actinic keratoses (AK) are among the most common dermatologic presentations, with estimates suggesting that they account for approximately 15 percent of dermatologic diagnoses in the US.1 Incidence of...
Read MoreFULL SUPPLEMENT: TIRBANIBULIN 1% OINTMENT FOR ACTINIC KERATOSIS LESS PAIN, MORE GAIN
October 2021 | Volume 20 | Issue 10 | Department | s3s | Copyright © October 2021
Topical agents for actinic keratosis (AK), along with cryotherapy and phototherapy, are the most commonly used therapies for areas of skin with multiple AKs. Multiple options for the topical treatment...
Read MoreUS Cutaneous Oncodermatology Management (USCOM): A Practical Algorithm
September 2021 | Volume 20 | Issue 9 | Supplement Individual Articles | 3ss | Copyright © September 2021
Background: An increasing number of patients survive or are living with cancer. Anticancer treatments frequently have cutaneous adverse events (cAEs) that may severely impact patients...
Read MoreFULL SUPPLEMENT: Skincare for Cancer Patients and Survivors
September 2021 | Volume 20 | Issue 9 | Department | 2s | Copyright © September 2021
Background: An increasing number of patients survive or are living with cancer. Anticancer treatments frequently have cutaneous adverse events (cAEs) that may severely impact patients...
Read MoreClinical Considerations for Integrating Gene Expression Profiling into Cutaneous Squamous Cell Carcinoma Management
June 2021 | Volume 20 | Issue 6 | Supplement Individual Articles | 5s | Copyright © June 2021
Gene expression profile (GEP) testing is now commercially available for metastatic risk prediction in patients with cutaneous squamous cell carcinoma (CSCC) and one or more high-risk factors. The purp...
Read MoreBridging the Gap: Integrating Gene Expression Profiling into Clinical Practice
June 2021 | Volume 20 | Issue 6 | Supplement Individual Articles | s4 | Copyright © June 2021
FULL SUPPLEMENT: Integrating Gene Expression Profiling into the Management of Cutaneous Squamous Cell Carcinoma
June 2021 | Volume 20 | Issue 6 | Department | 1ss | Copyright © June 2021
This supplement provides an early framework for healthcare providers looking to integrate patient-specific tumor biology into their clinical practice using GEP testing. Gene expression profile (GEP) t...
Read MoreARTICLE: Advances in Oral Isotretinoin Therapy
May 2021 | Volume 20 | Issue 5 | Supplement Individual Articles | s5 | Copyright © May 2021
Since its approval in 1982, oral isotretinoin has revolutionized acne therapy. However, oral isotretinoin use has long been associated with challenges of variable bioavailability and food dependence. ...
Read MoreARTICLE: Why Absorica LD?
May 2021 | Volume 20 | Issue 5 | Supplement Individual Articles | 3s | Copyright © May 2021
FULL SUPPLEMENT: Status Update: Isotretinoin
May 2021 | Volume 20 | Issue 5 | Department | 1s | Copyright © May 2021
